APOE and Alzheimer disease: Perhaps not surprisingly, APOE e4 was significantly associated with conversion risk (OR = 4.63) and rapid progression (HR 1.77), while CLU was associated with decreased conversion risk (OR 0.25), which is in agreement with previous studies suggesting that it has a neuroprotective role in AD pathogenesis (41).